Introduction

Malignant melanoma is a cancer of the melanocytes having a 5-year survival rate of only 15–20% once the tumor has metastasized to distant tissues [1]. Over the last few decades the incidence of melanoma has been increasing rapidly in males compared to females of all ages, with the exception of young women (≤39 years) who appear to be at higher risk than young men [2–4]. Yet, women appear to have a survival advantage over men that is not yet understood. Epidemiological studies have confirmed sex as an independent prognostic factor after adjusting for other known predictive markers including age, Breslow thickness, ulceration, histologic subtype, location, and sentinel lymph node positivity [5–9].

Abstract

Women diagnosed with cutaneous melanoma have a survival advantage compared to men, which has been hypothesized to be due to difference in behavior and/or biology (sex hormones). It remains controversial whether this advantage is dependent on age or stage of disease. We sought to compare melanoma-specific survival between females in pre, peri, and postmenopausal age groups to males in the same age group, adjusting for stage of disease. This is a retrospective population-based cohort study using the Surveillance, Epidemiology, and End Results (SEER) database. Patients diagnosed from 1 January 1992 through 31 January 2011 with primary invasive cutaneous melanoma were included in our cohort. Melanoma-specific survival was the main outcome studied.

Of the 106,511 subjects that were included, 45% were female. Females in all age groups (18–45, 46–54, and ≥55) with localized and regional disease, were less likely to die from melanoma compared to males in the same age group. Among patients with localized and regional disease, the relative risk of death due to melanoma increased with advancing age at diagnosis; this increase was more pronounced among females than males. In contrast, we observed no female survival advantage among patients with distant disease and no effect of age on relative risk of death from melanoma. Females with localized and regional melanoma have a decreased risk of death compared to males within all age groups. Our data show no differences in survival between men and women with metastatic melanoma, indicating that the influence of sex on survival is limited to early stage disease but not confined to pre or perimenopausal age groups.
an independent prognostic factor after adjustment for lifestyle, nor why the female survival advantage has been observed across continents with vast differences in healthcare delivery [11].

In regard to biology, many studies have shown clear differences in pharmacokinetics, responses to infection/inflammation and hormones between the two sexes [12]. Significant differences exist in the absorption, distribution, metabolism, and elimination of drugs between sexes; thus, outcomes in clinical (and animal) research should be reported separately by sex [13, 14]. Although melanoma is not classically thought of as a hormone responsive tumor, androgen receptors have been detected on melanoma cells, which may explain why this cancer is more aggressive in men [15]. Estrogen may also play a role as some reports suggest the female survival advantage is abrogated in postmenopausal females as estrogen levels decline [16, 17]. While some investigators have hypothesized that sex influences only local tumor invasion [18], others believe that the effect is limited to lymphatic or hematogenous metastasis [19, 20]. However, studies in patients with metastatic disease are limited and have thus far yielded conflicting results [21–23].

Thus, we elected to investigate the relationship between sex and survival by utilizing the Surveillance, Epidemiology, and End Results (SEER) database. Specifically, our aim was to delineate whether the survival advantage in women is restricted to early stage malignant melanoma, as

| Characteristic                        | Female (N = 47,687) | Male (N = 58,824) | Total (N = 106,511) |
|--------------------------------------|---------------------|-------------------|---------------------|
| Age at diagnosis (years)             |                     |                   |                     |
| 18–45                                | 17,157 (36.0%)      | 1275 (21.7%)      | 29,916 (28.1%)      |
| 46–54                                | 9156 (19.2%)        | 11,013 (18.7%)    | 20,169 (18.9%)      |
| ≥55                                  | 21,374 (44.8%)      | 3505 (59.6%)      | 56,426 (53.0%)      |
| Race, n (%)                          |                     |                   |                     |
| American Indian/Alaska native        | 112 (0.2%)          | 120 (0.2%)        | 232 (0.2%)          |
| Asian or Pacific Islander            | 480 (1.0%)          | 466 (0.8%)        | 946 (0.9%)          |
| Black                                | 278 (0.6%)          | 242 (0.4%)        | 520 (0.5%)          |
| Unknown                              | 1513 (3.2%)         | 1586 (2.7%)       | 3099 (2.9%)         |
| White                                | 45,304 (95.0%)      | 56,410 (95.9%)    | 101,714 (95.5%)     |
| Ethnicity among Whites, n (%)        |                     |                   |                     |
| Non-Spanish-Hispanic-Latino          | 43,370 (95.7%)      | 55,067 (97.6%)    | 98,437 (96.8%)      |
| Spanish-Hispanic-Latino              | 1934 (4.3%)         | 1343 (2.4%)       | 3277 (3.2%)         |
| Ethnicity, n (%)                     |                     |                   |                     |
| Non-Spanish-Hispanic-Latino          | 45,694 (95.8%)      | 57,439 (97.6%)    | 103,133 (96.8%)     |
| Spanish-Hispanic-Latino              | 1993 (4.2%)         | 1385 (2.4%)       | 3378 (3.2%)         |
| Stage at diagnosis, n (%)            |                     |                   |                     |
| Distant (stage IV)                   | 1212 (2.5%)         | 2460 (4.2%)       | 3672 (3.4%)         |
| Localized (stage I-II)               | 40,968 (85.9%)      | 47,900 (81.4%)    | 88,868 (83.4%)      |
| Regional (stage III)                 | 4054 (8.5%)         | 6530 (11.1%)      | 10,584 (9.9%)       |
| Unstaged                             | 1453 (3.0%)         | 1934 (3.3%)       | 3387 (3.2%)         |
| Breslow depth, n (%)                 |                     |                   |                     |
| No mass/tumor found                  | 367 (0.8%)          | 790 (1.3%)        | 1157 (1.1%)         |
| 0.01–1.00 mm                         | 31,076 (65.2%)      | 34,428 (58.5%)    | 65,504 (61.5%)      |
| 1.01–2.00 mm                         | 6061 (12.7%)        | 8535 (14.5%)      | 14,596 (13.7%)      |
| 2.01–4.00 mm                         | 3149 (6.6%)         | 4949 (8.4%)       | 8098 (7.6%)         |
| >4.00 mm                             | 1819 (3.8%)         | 3193 (5.4%)       | 5012 (4.7%)         |
| Unknown                              | 5215 (10.9%)        | 6929 (11.8%)      | 12,144 (11.4%)      |
| Histologic subtype, n (%)            |                     |                   |                     |
| Superficial spreading                | 18,466 (38.7%)      | 19,857 (33.8%)    | 38,323 (36.0%)      |
| Lentigo maligna                      | 2278 (4.8%)         | 4577 (7.8%)       | 6855 (6.4%)         |
| Acral lentigous                      | 662 (1.4%)          | 565 (1.0%)        | 1227 (1.2%)         |
| Nodular                              | 2947 (6.2%)         | 4622 (7.9%)       | 7569 (7.1%)         |
| NOS                                  | 21,480 (45.0%)      | 26,516 (45.1%)    | 47,996 (45.1%)      |
| Others                               | 1854 (3.9%)         | 2687 (4.6%)       | 4541 (4.3%)         |
| Anatomic site, n (%)                 |                     |                   |                     |
| Face/ears                            | 4146 (8.7%)         | 8461 (14.4%)      | 12,607 (11.8%)      |
| Scalp/neck                           | 1833 (3.8%)         | 5351 (9.1%)       | 7184 (6.7%)         |
| Trunk                                | 12,319 (25.8%)      | 23,433 (39.8%)    | 35,752 (33.6%)      |
| Extremities                          | 27,975 (58.7%)      | 18,975 (32.3%)    | 46,950 (44.1%)      |
| NOS/overlapping                      | 1414 (3.0%)         | 2604 (4.4%)       | 4018 (3.8%)         |
previously reported, or whether it may persist in advanced or metastatic disease. Herein, we compare the risk of death due to melanoma across all stages of the disease, exploring the possible sex effect using age groups as a proxy for menopausal status in women.

Figure 1. Relative risk of death due to melanoma by sex and age at diagnosis, according to disease stage. In each figure, 40-year-old females are the reference (relative risk of 1). (A) localized; (B) regional; (C) distant.

Methods

Study data

We identified cases with a diagnosis of melanoma reported to the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program between 1 January 1992 and 31 December 2011. SEER*Stat version 8.2.1 software (National Cancer Institute, Bethesda, MD; http://www.seer.cancer.gov/seerstat; accessed 17 June 2015) was used to obtain de-identified individual-level data from 13 cancer registries. Cases of melanoma were identified by specifying site “melanoma of the skin,” which included cases with International Classification of Diseases for Oncology, Third Edition (ICD-0-3) codes 8720–8723, 8726–8727, 8730, 8740–8746, 8760–8761, 8770–8773, 8780, and 8790. The analysis was limited to patients 18 years or older who had microscopically confirmed invasive cutaneous melanoma.

First primary diagnosis of melanoma was used and patients were excluded if the report was obtained solely from a death certificate or autopsy report, they had a prior history of another cancer, they had in situ melanoma only with no documented invasive disease, they were alive at last follow-up with 0 months of follow-up or the cause of death was unknown. Cases were categorized by histologic subtype as superficial spreading, lentigo maligna, acral lentiginous, nodular, not otherwise specified and other. Histologic category “not otherwise specified” and “other” was not collapsed because the survival patterns were different. As the staging system for melanoma was revised in the American Joint Committee on Cancer (AJCC) Cancer staging manual and was implemented into registries in 2003, SEER historic stage was used. These stages include localized (confined to primary organ, the skin), regional (spread to surrounding organs or local lymph nodes), distant (spread to remote organs from primary tumor or to distant lymph nodes), and unknown. Anatomic sites were classified as face/ear (C440–C443), scalp and neck (C444), trunk (C445), extremities (C446–C447), and not otherwise specified/overlapping codes (C448–C449). Scalp and neck melanomas were analyzed separately because they have poorer survival than melanomas of the face, ear and other anatomic sites [24]. Information on race and ethnicity was obtained from tumor registrars who reported melanoma to the SEER program. Identification of cases having Hispanic ethnicities was enhanced with the North American Association of Central Cancer Registries Hispanic Identification Algorithm [25]. Vital status and cause of death were obtained through 31 December 2012. Patients were categorized into three groups using age as a proxy for menopausal status in women: age 18–45
for premenopausal, 46–54 for perimenopausal, and 55 and older for postmenopausal.

**Statistical analysis**

Statistical analyses were performed using the SAS version 9.3 software package and R version 3.0.2. The outcome of interest was death due to melanoma; survival time was calculated from the date of diagnosis to the date of death or last follow-up. Outcome results were stratified by disease stage. The effect of sex and age at diagnosis on death due to melanoma was evaluated two ways. First, the predicted log hazards were estimated in a Cox proportional hazards model that included sex, age as a continuous variable, and their interaction. The nonlinear effect of age was modeled using a penalized smoothing spline with a pspline basis. Forty-year-old females were chosen as the reference in the graphical display of relative risk of death due to melanoma versus age [26]. Second, stratified by the three prespecified age groups, melanoma-specific survival was estimated separately for males and females using the Kaplan–Meier method and Cox models were fit to evaluate the association between sex and death due to melanoma. These analyses were conducted for the overall cohort at baseline and for cohorts defined on the condition of surviving 1, 3, or 5 years following melanoma diagnosis. Lastly, additional Cox models were fit to evaluate the association between sex and death due to melanoma within strata defined by Breslow depth, histologic subtype, anatomic site, and stage distant disease. Associations were summarized using the hazard ratios (HR) and corresponding 95% confidence intervals (CI) derived from the parameter estimates in the Cox models. The proportional hazards assumption for the Cox models were graphically assessed by plotting the scaled Schoenfeld residuals as a function of rank follow-up time and the assumption was not violated for sex or age. All calculated P-values were two-sided and P-values less than 0.05 were considered statistically significant.

**Results**

From 1992 to 2011, 201,719 cases of melanoma of the skin were identified in the SEER database. Patient exclusions as defined above were for a diagnosis of melanoma in situ (n = 75,634), a history of prior cancer (n = 17,331), no pathology confirmation of melanoma (n = 519), diagnosis solely from a death certificate or autopsy report (n = 12), unknown cause of death was unknown (n = 509), and survival time of 0 months or not available (n = 1203).

Our final study population consisted of 106,511 patients with invasive cutaneous melanoma (Table 1). Of these patients, 55.2% were male and 44.8% were female. Of the melanoma cases identified in females, the greatest number of cases (44.8%) was identified in the postmenopausal group, followed by the premenopausal (36.0%) and perimenopausal age groups (19.2%). The majority of melanoma cases identified in males were seen in the over 55 age group (59.6%). Most patients were Caucasian of non-Spanish-Hispanic-Latino ethnicity having thin melanomas of 0.01–1.00 mm Breslow depth. Superficial spreading was the most common specified histology. In regard to anatomical site, the extremities were the most common location for melanoma (44.1%), followed by the trunk (33.6%), the face and ears (11.8%), and the scalp and neck (6.7%). As expected, males reported more head, neck and trunk melanomas compared with females who had melanoma most often on their extremities.

| Stage                        | Age group (years) | No. of deaths due to melanoma/no. of patients | HR (95% CI) males versus females | P-value |
|------------------------------|-------------------|-----------------------------------------------|----------------------------------|---------|
| Localized disease            | 18–45             | 501/10,528                                    | 2.05 (1.79, 2.35)                | <0.001  |
| (stage I–II)                 | 46–54             | 510/9113                                      | 1.89 (1.62, 2.20)                | <0.001  |
|                              | ≥55               | 1845/28,259                                   | 1.42 (1.30, 1.54)                | <0.001  |
| All ages, age adjusted¹      |                   | 2856/47,900                                   | 1.59 (1.49, 1.70)                | <0.001  |
| Regional disease             | 18–45             | 500/1400                                      | 1.65 (1.42, 1.92)                | <0.001  |
| (stage III)                  | 46–54             | 430/1144                                      | 1.40 (1.18, 1.66)                | <0.001  |
|                              | ≥55               | 1514/3986                                     | 1.25 (1.14, 1.36)                | <0.001  |
| All ages, age adjusted¹      |                   | 2444/6530                                     | 1.37 (1.28, 1.47)                | <0.001  |
| Distant disease (stage IV)   | 18–45             | 298/411                                       | 1.14 (0.93, 1.38)                | 0.21    |
|                              | 46–54             | 303/446                                       | 1.07 (0.86, 1.33)                | 0.57    |
|                              | ≥55               | 1105/1603                                     | 1.09 (0.99, 1.21)                | 0.09    |
| All ages, age adjusted¹      |                   | 1706/2460                                     | 1.10 (1.01, 1.20)                | 0.028   |

HR, hazard ratio; CI, confidence interval.

¹ Age as a continuous variable, not categorized into three age groups, was included in the Cox proportional hazards models.
Melanoma-specific survival

Among the 47,687 females, 3,638 (7.6%) died due to melanoma, 5,787 (12.1%) died due to other causes, and 38,262 (80.2%) were alive at last follow-up. Among the 58,824 males, 7,411 (7.6%) died due to melanoma, 10,246 (17.4%) died due to other causes, and 41,167 (70.0%) were alive at last follow-up. The median (IQR, interquartile range) duration of follow-up after melanoma diagnosis was 8.2 (4.3–13.3) and 7.8 (4.0–12.9) years for females and males, respectively. The median time to death due to melanoma was 2.3 (0.9–4.8) and 2.2 (4.0–0.9–4.3) years for females and males, respectively.

Figure 1 illustrates the effect of sex and age on the risk of death due to melanoma, separately by stage of disease. Age was evaluated as a continuous variable and the nonlinear effect of age was modeled using a penalized smoothing spline. In each figure, 40-year-old females were chosen as the referent (relative risk of 1). Among patients with localized and regional disease, the relative risk of death due to melanoma increased with advancing age at diagnosis; however, this increase was more pronounced among females than males. The relative risk of death from melanoma did not vary with age at diagnosis among patients with distant disease.

Among patients with localized disease, the risk of death due to melanoma was greater in men than women after adjusting for age (HR 1.59, 95% CI 1.49–1.70). This increased risk in males versus females was greatest in the 18–45 age group (HR 2.05, CI 1.79–2.35) followed by the 46–54 age group (HR 1.89, CI 1.62–2.20) and the ≥55 age group (HR 1.42, CI 1.30–1.54) (Table 2, Fig. 2). Among patients with regional disease, the risk of death due to melanoma for males was 1.4 times that of females after adjusting for age (HR 1.37, 95% CI 1.28–1.47). This increased risk was also greatest in the 18–45 age group. In contrast, among patients with distant disease, females were just as likely as males to die of melanoma (HR 1.10, 95% CI 1.01–1.20) after adjusting for age. The analyses were repeated to further adjust for calendar year of diagnosis and given that there were no appreciable differences in the hazard ratios for the sex effect the results adjusted for calendar year have not been presented.

Comparison between males and females of melanoma-specific survival conditional on surviving 1, 3, or 5 years following diagnosis are summarized in Table 3 and Figure 3. The survival advantage for female patients with localized disease persisted for all 3 age groups even among patients who survived 5 years after diagnosis. This was also observed for patients with regional disease diagnosed between 18 and 45 years of age. For patients with regional disease diagnosed between 46 and 54 years of age, patient sex no longer significantly differentiated survival after 2 years of conditional survival from melanoma (HR 1.22, 95% CI 0.98–1.52, figure not shown). For patients with regional disease diagnosed at 55 years of age and older, patient sex no longer significantly differentiated survival after 5 years of conditional survival from melanoma. (HR 1.17, 95% CI 0.93–1.47).

Among patients with localized disease, the risk of death due to melanoma was consistently greater in males than
females regardless of Breslow depth, histologic subtype, or anatomical location (Table 4). Among patients with regional disease, the risk of death due to melanoma was consistently greater in males than females regardless of the Breslow depth or histologic subtype, except the association was attenuated among the small subset with lentigo maligna. In addition, the risk of death due to melanoma was consistently greater in males than females with melanoma on the face/ears, trunk, or extremities, but the risk was not differentially elevated among those with melanoma on the scalp or neck.

The site of distant disease was available in SEER for 1651 of the 1813 patients with melanoma who presented with stage IV disease diagnosed from 2004 to 2011. Table 5 summarizes the association between sex and death due to melanoma stratified by stage.

### Discussion

Many studies have found a female survival advantage among patients with melanoma which is independent of differences in detection or diagnosis. As no biological rationale for this advantage has been fully identified, we analyzed melanoma-specific survival between males and females for different stages of disease and different age groups to explore whether there might be an association with hormonal status. Although previous studies using the SEER database have suggested a female survival benefit in patients with melanoma of the head and neck and in non-Hispanic patients under the age of 40, neither of these studies analyzed survival in regards to age and tumor stage as was done in this study [8, 27]. Our results confirmed the female survival benefit among patients treated for early stage melanoma, namely localized (stage I and II) and regional (stage III) disease; however, not for patients with distant (stage IV) disease. Our results seem contradictory from a recently reported analysis of three large European clinical trials showing that females with distant disease maintained a survival benefit compared to male patients [7]. While both our study and the European study looked at patients over similar time periods, we used the SEER database and included patients who received any treatment for distant disease, whereas the previous study looked only at patients who received one of four possible chemotherapies, all of which included an alkylating agent such as dacarbazine or temozolomide. Their results may have been confounded by the fact that women respond better to both dacarbazine and temozolomide compared to men [28, 29]. Similar to our findings, the female survival advantage seemed to decrease in patients with higher metastatic tumor burden [7]. Studies using other large registries, which included therapies other than alkylating agents, similarly did not detect a female survival benefit for patients with distant disease [21, 23]. Clearly there is a need to clarify the biology behind these contradictory conclusions.

---

**Table 3.** Association between sex and death due to melanoma, stratified by stage and age at diagnosis, conditional on surviving 1, 3, or 5 years, respectively.

| Stage                  | Age group (years) | Death due to melanoma conditional on surviving 1 year | Death due to melanoma conditional on surviving 3 years | Death due to melanoma conditional on surviving 5 years |
|------------------------|-------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                        |                   | HR (95% CI) males versus females | P-value | HR (95% CI) males versus females | P-value | HR (95% CI) males versus females | P-value |
| Localized disease      |                   |                                      |         |                                      |         |                                      |         |
| (stage I–II)           | 18–45             | 2.03 (1.77, 2.33)                   | <0.001  | 1.85 (1.58, 2.17)                   | <0.001  | 1.69 (1.39, 2.05)                   | <0.001  |
|                        | 46–54             | 1.90 (1.63, 2.23)                   | <0.001  | 1.83 (1.52, 2.20)                   | <0.001  | 1.82 (1.45, 2.29)                   | <0.001  |
|                        | ≥55               | 1.42 (1.30, 1.54)                   | <0.001  | 1.40 (1.25, 1.56)                   | <0.001  | 1.42 (1.23, 1.63)                   | <0.001  |
|                        | All ages, age adjusted | 1.60 (1.50, 1.71)                   | <0.001  | 1.57 (1.45, 1.70)                   | <0.001  | 1.55 (1.40, 1.72)                   | <0.001  |
| Regional disease       |                   |                                      |         |                                      |         |                                      |         |
| (stage III)            | 18–45             | 1.64 (1.40, 1.93)                   | <0.001  | 1.46 (1.16, 1.83)                   | 0.001   | 1.61 (1.16, 2.23)                   | 0.004   |
|                        | 46–54             | 1.30 (1.08, 1.56)                   | 0.005   | 1.11 (0.85, 1.46)                   | 0.44    | 0.94 (0.65, 1.38)                   | 0.76    |
|                        | ≥55               | 1.34 (1.21, 1.48)                   | <0.001  | 1.27 (1.09, 1.49)                   | 0.003   | 1.17 (0.93, 1.47)                   | 0.19    |
|                        | All ages, age adjusted | 1.41 (1.31, 1.52)                   | <0.001  | 1.30 (1.15, 1.46)                   | <0.001  | 1.23 (1.04, 1.46)                   | 0.017   |
| Distant disease        |                   |                                      |         |                                      |         |                                      |         |
| (stage IV)             | 18–45             | 1.41 (0.99, 2.01)                   | 0.06    | 1.67 (0.75, 3.71)                   | 0.20    | 1.76 (0.52, 5.88)                   | 0.36    |
|                        | 46–54             | 0.94 (0.64, 1.38)                   | 0.75    | 1.03 (0.49, 2.19)                   | 0.93    | 0.85 (0.26, 2.76)                   | 0.78    |
|                        | ≥55               | 1.07 (0.88, 1.30)                   | 0.50    | 0.88 (0.59, 1.30)                   | 0.51    | 0.82 (0.39, 1.70)                   | 0.59    |
|                        | All ages, age adjusted | 1.10 (0.95, 1.29)                   | 0.21    | 1.02 (0.75, 1.41)                   | 0.88    | 0.97 (0.56, 1.68)                   | 0.92    |

HR, hazard ratio; CI, confidence interval.

1Age as a continuous variable, not categorized into three age groups, was included in the Cox proportional hazards models.
It’s been suggested by some that females continue to have superior survival with increasing age compared to males following both localized and regional melanoma diagnoses [7, 23, 30]. Conversely, others have shown no survival difference between male and female melanoma patients with increasing age, mainly due to an increasing risk of death with age in females [6, 16]. Traditionally, women of all age groups tend to visit their health care providers more frequently, avoid excessive sun exposure and complete skin checks compared to men [10]. Yet, these behavioral differences between men and women cannot fully account for the observed differences in cancer survival. Although the survival advantage for females decreased with the advancing age group at diagnosis, among the patients with localized disease in the ≥55 age group we found men were still 1.4 times more likely than women to die due to melanoma. Unsurprisingly, both males and females had increasing risk of death due to melanoma with increasing age at diagnosis. However, this increase was steeper for women than for men, suggesting that age alone is not the only contributing factor.

Although our study suggests a potential association of estrogen with melanoma based on the finding of improved survival in women with local and regional disease, many
Epidemiologic reports suggest that estrogens do not affect melanoma citing studies of oral contraceptives, hormone replacement therapy and pregnancy [31]. Conversely, others have found estrogen receptor (ER)β is expressed on metastatic melanoma tumors and loss of expression results in increased tumor invasion [32]. ERβ expression has also been shown to decline after menopause, which may explain the loss of the female survival advantage in women over 55 [33]. Clearly collecting specific information on menopausal status and exogenous hormone use (inclusive of contraception, menopausal therapy, and antiestrogen therapy used as part of treatment and prevention of other hormone-sensitive neoplasms) will be essential for future research on the effects of sex hormones on the incidence, prognosis, and survival of patients diagnosed with melanoma. As estrogen could have a protective role due to the observed better outcome in females with melanoma, we analyzed survival using age as a proxy for menopausal status and observed a survival advantage for women across all age groups compared to men.

While a female survival benefit was seen for patients with localized and regional disease in all age categories, we did not observe similar differences in patients with distant disease and higher tumor burden. One postulated reason could be the drastically different immunologic changes associated with metastatic melanoma compared to earlier stages of disease. For instance, systemic immunity is biased toward a state of chronic inflammation in patients with distant disease that is not seen in patients with early stage melanoma or healthy volunteers [34]. Aging is also associated with increased markers of chronic inflammation which may play a role in the decreased

**Table 4.** Among patients with localized (stage I–II) and regional disease (stage III), separately, association between sex and death due to melanoma, stratified by melanoma characteristics.

| Characteristic                  | No. of deaths due to melanoma/no. of patients | HR (95% CI) males versus females | P-value |
|--------------------------------|-----------------------------------------------|---------------------------------|---------|
| Breslow depth (mm), n (%)      |                                               |                                 |         |
| 0.01–0.99 mm                   | 1255/63,285                                   | 1.76 (1.57, 1.98)               | <0.001  |
| 1.00–2.00 mm                   | 1179/12,187                                   | 1.57 (1.39, 1.78)               | <0.001  |
| 2.01–4.00 mm                   | 1023/5194                                     | 1.46 (1.28, 1.66)               | <0.001  |
| >4.00 mm                       | 436/1178                                      | 1.59 (1.29, 1.96)               | <0.001  |
| Unknown                        | 386/9421                                      | 1.55 (1.26, 1.90)               | <0.001  |
| Histologic subtype, n (%)      |                                               |                                 |         |
| Superficial spreading          | 1259/35,694                                   | 1.87 (1.66, 2.10)               | <0.001  |
| Lentigo maligna                | 173/6508                                      | 2.26 (1.54, 3.32)               | <0.001  |
| Acral lentignous               | 89/784                                        | 1.50 (0.99, 2.28)               | 0.06    |
| Nodular                       | 865/4559                                      | 1.72 (1.48, 1.98)               | <0.001  |
| NOS                            | 1694/38,169                                   | 1.70 (1.54, 1.88)               | <0.001  |
| Others                         | 199/3154                                      | 1.83 (1.35, 2.48)               | <0.001  |
| Anatomic site, n (%)           |                                               |                                 |         |
| Face/ears                      | 591/10,833                                    | 1.69 (1.40, 2.04)               | <0.001  |
| Scalp/neck                     | 517/5629                                      | 1.38 (1.12, 1.70)               | 0.003   |
| Trunk                          | 1588/31,276                                   | 1.55 (1.39, 1.73)               | <0.001  |
| Extremities                    | 1560/40,687                                   | 1.77 (1.60, 1.96)               | <0.001  |
| NOS/overlapping                | 23/443                                        | 1.67 (0.69, 4.07)               | 0.26    |

**Table 5.** Association between sex and death due to melanoma, stratified by site of distant disease among patients diagnosed with distant disease (stage IV) in 2004–2011.

| Site of distant disease | No. of deaths due to melanoma/no. of patients | HR (95% CI) males versus females | P-value |
|-------------------------|-----------------------------------------------|---------------------------------|---------|
| M1a                     | 78/144                                        | 35/78                           | 1.37 (0.92, 2.04) | 0.12 |
| M1b                     | 89/133                                        | 43/71                           | 1.11 (0.77, 1.60) | 0.56 |
| M1c                     | 605/845                                       | 251/371                         | 1.02 (0.88, 1.18) | 0.77 |
| Unknown                 | 40/101                                        | 22/61                           | –               | –    |

HR, hazard ratio; CI, confidence interval.
survival of older patients with all stages of melanoma [35]. New therapies that harness the immune system to destroy the tumor have had great success in melanoma, indicating the importance of host immunity for improved survival [36]. Since immune checkpoint agents have only recently been FDA approved for melanoma, it is unlikely that patients taking immune checkpoint inhibitors are represented in this study. With more patients being treated with these therapies, it will be important to look for sex differences in survival and side effect profiles in this population.

We are limited in that our dataset only allowed us to evaluate age and not actual menopausal status to address the role of menopause in mediating melanoma survival. Additionally, hormone use, patient comorbidities, treatment preferences and other possible factors that influence survival were unavailable with the SEER database. Due to the fact that the AJCC staging system was only implemented into registries in 2003, we elected to use the SEER historic stage for all patients. We performed additional analyses regarding the association between sex and death due to melanoma for localized and regional disease patients stratified by melanoma characteristics such as Breslow depth, histopathological subtype, and anatomic site. These limitations should be weighed against the strengths of the SEER including population-based data, referral bias elimination, detailed tumor information and large sample size to adequately power analyses. Nevertheless, we believe that this study provides a rationale for further studies investigating hormonal- and sex-based differences in the outcome of malignant melanoma and the effect of sex on response to melanoma therapies.

In summary, this study utilizes the SEER database to study the female survival advantage not only in localized and regional melanoma, but also in patients presenting with distant disease. The large number of patients allowed us to more clearly describe the epidemiologic pattern of melanoma-specific survival in the United States in men and women across three different age groups. Data from our study indicate that, compared to males, females have improved survival for localized and regional disease, but that this sex difference is lost among patients presenting with distant disease. Further study of the biological and environmental differences between male and female patients is warranted. Understanding the basis for these differences has the potential to improve outcomes for cutaneous melanoma patients.

Conflict of Interest
None declared.

References
1. Siegel, R. L., K. D. Miller, and A. Jemal. 2016. Cancer statistics, 2016. CA Cancer J. Clin. 66:7–30.
2. Robsahm, T. E., G. Bergva, U. E. Hestvik, and B. Moller. 2013. Sex differences in rising trends of cutaneous malignant melanoma in Norway, 1954–2008. Melanoma Res. 23:70–78.
3. Weir, H. K., L. D. Marrett, V. Cokkinides, J. Barnholtz-Sloan, P. Patel, E. Tai, et al. 2011. Melanoma in adolescents and young adults (ages 15–39 years): United States, 1999–2006. J. Am. Acad. Dermatol. 65(5 Suppl 1):S38–S49.
4. Reed, K. B., J. D. Brewer, C. M. Lohse, K. E. Bringe, C. N. Pruitt, and L. E. Gibson. 2012. Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin. Proc. 87:328–334.
5. Balch, C. M., S. J. Soong, J. E. Gershenwald, J. F. Thompson, D. S. Reintgen, N. Cascinelli, et al. 2001. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19:3622–3634.
6. Lasithiotakis, K., U. Leiter, F. Meier, T. Eigentler, G. Metzler, M. Moehrle, et al. 2008. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 112:1795–1804.
7. Joosses, A., S. Collette, S. Suciu, T. Nijsten, P. M. Patel, U. Keilholz, et al. 2013. Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials. J. Clin. Oncol. 31:2337–2346.
8. Gamba, C. S., C. A. Clarke, T. H. Keegan, L. Tao, and S. M. Swetter. 2013. Melanoma survival disadvantage in young, non-Hispanic white males compared with females. JAMA Dermatol. 149:912–920.
9. Downing, A., J. A. Newton-Bishop, and D. Forman. 2006. Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993-2003. Br. J. Cancer 95:91–95.
10. Courtenay, W. H. 2000. Constructions of masculinity and their influence on men’s well-being: a theory of gender and health. Soc. Sci. Med. 50:1385–1401.
11. Micheli, A., R. Ciampichini, W. Oberaigner, L. Ciccolallo, E. de Vries, I. Izarzuguaza, et al. 2009. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur. J. Cancer 45:1017–1027.
12. Pardue, M. L. 2001. Exploring the biological contributions to human health: does sex matter? National Academies Press (US), Washington (DC).
13. Soldin, O. P., and D. R. Mattison. 2009. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 48:143–157.
14. Clayton, J. A., and C. Tannenbaum. 2016. Reporting sex, gender, or both in clinical research? JAMA 316:1863–1864.
15. Morvillo, V., I. A. Luthy, A. I. Bravo, M. I. Capurro, P. Portela, R. S. Calandra, et al. 2002. Androgen receptors in human melanoma cell lines IIB-MEL-LES and IIB-MEL-IAN and in human melanoma metastases. Melanoma Res. 12:529–538.
16. Mervic, L., U. Leiter, F. Meier, T. Eigentler, A. Forschner, G. Metzler, et al. 2011. Sex differences in survival of cutaneous melanoma are age dependent: an analysis of 7338 patients. Melanoma Res. 21:244–252.
17. Kemeny, M. M., E. Busch, A. K. Stewart, and H. R. Menck. 1998. Superior survival of young women with malignant melanoma. Am. J. Surg. 175:437–444; discussion 44–45.
18. Molife, R., P. Lorigan, and S. MacNeil. 2001. Gender and survival in malignant tumours. Cancer Treat. Rev. 27:201–209.
19. Richardson, B., A. Price, M. Wagner, V. Williams, P. Lorigan, S. Browne, et al. 1999. Investigation of female survival benefit in metastatic melanoma. Br. J. Cancer 80:2025–2033.
20. Scoggins, C. R., M. I. Ross, D. S. Reintgen, R. D. Noyes, J. S. Goydos, P. D. Beitsch, et al. 2006. Gender-related differences in outcome for melanoma patients. Ann. Surg. 243:693–698; discussion 98–700.
21. Unger, J. M., L. E. Flaherty, P. Y. Liu, K. S. Albain, and V. K. Sondak. 2001. Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer 91:1148–1155.
22. Korn, E. L., P. Y. Liu, S. J. Lee, J. A. Chapman, D. Niedzwiecki, V. J. Suman, et al. 2008. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 26:527–534.
23. Joosse, A., E. de Vries, R. Eckel, T. Nijsten, A. M. Eggermont, D. Holzel, et al. 2011. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J. Invest. Dermatol. 131:719–726.
24. Tarkin, S. A., A. E. Mikhail, K. V. Shelekhova, O. S. Frolova, and A. O. Nefedov. 2013. Clinical course of cutaneous melanoma of the head and neck, and the factors affecting patient survival. Vopr. Onkol. 59:114–117.
25. Pollack, L. A., J. Li, Z. Berkowitz, H. K. Weir, X. C. Wu, U. A. Ajani, et al. 2011. Melanoma survival in the United States, 1992 to 2005. J. Am. Acad. Dermatol. 65(3 Suppl 1):1030.
26. Therneau, T. 2017. Spline terms in a Cox model. Self-published at: https://cran.r-project.org/web/packages/survival/vignettes/splines.pdf
27. Arce, P. M., P. R. Camilion, W. A. Stokes, S. A. Nguyen, and E. J. Lentsch. 2014. Is sex an independent prognostic factor in cutaneous head and neck melanoma? Laryngoscope 124:1363–1367.
28. Stupp, R., W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352:987–996.
29. Mulder, N. H., W. T. van der Graaf, P. H. Willemsen, H. S. Koops, E. G. de Vries, and D. T. Sleijfer. 1994. Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma. Br. J. Cancer 70:681–683.
30. Joosse, A., S. Collette, S. Sicu, T. Nijsten, F. Lejeune, U. R. Kleeberg, et al. 2012. Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J. Clin. Oncol. 30:2240–2247.
31. Gupta, A., and M. S. Driscoll. 2010. Do hormones influence melanoma? Facts and controversies Clin. Dermatol. 28:287–292.
32. Schmidt, A. N., L. B. Nanney, A. S. Boyd, L. E. Jr King, and D. L. Ellis. 2006. Estrogen receptor-beta expression in melanocytic lesions. Exp. Dermatol. 15:971–980.
33. de Giorgi, V., A. Gori, S. Gandini, F. Papic, M. Grazzini, S. Rossari, et al. 2013. Oestrogen receptor beta and melanoma: a comparative study. Br. J. Dermatol. 168:513–519.
34. Nevala, W. K., C. M. Vachon, A. A. Leontovich, C. G. Scott, M. A. Thompson, and S. N. Markovic. 2009. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin. Cancer Res. 15:971–980.
35. Mansfield, A. S., W. K. Nevala, R. S. Dronca, A. A. Leontovich, L. Shuster, and S. N. Markovic. 2012. Normal aging is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes. Clin. Exp. Immunol. 170:186–193.
36. Hauschild, A., and C. Garbe. 2015. Immunotherapy: combined immunotherapy—a new standard in metastatic melanoma? Nat. Rev. Clin. Oncol. 12:439–440.